J
Joan Carles
Researcher at Hebron University
Publications - 247
Citations - 13057
Joan Carles is an academic researcher from Hebron University. The author has contributed to research in topics: Prostate cancer & Enzalutamide. The author has an hindex of 37, co-authored 212 publications receiving 10822 citations. Previous affiliations of Joan Carles include Autonomous University of Barcelona & University of Barcelona.
Papers
More filters
Journal ArticleDOI
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer,Andrew J. Armstrong,Dana E. Rathkopf,Yohann Loriot,Cora N. Sternberg,Celestia S. Higano,Peter Iversen,Suman Bhattacharya,Joan Carles,Simon Chowdhury,Ian D. Davis,Johann S. de Bono,Christopher P. Evans,Karim Fizazi,Anthony M. Joshua,Choung-Soo Kim,Go Kimura,Paul N. Mainwaring,Harry H. Mansbach,Kurt Miller,Sarah B. Noonberg,Frank Perabo,De Phung,Fred Saad,Howard I. Scher,Mary-Ellen Taplin,Peter Venner,Bertrand Tombal +27 more
TL;DR: Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer.
Journal ArticleDOI
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan,Matthew R. Smith,Johann S. de Bono,Arturo Molina,Christopher J. Logothetis,Paul de Souza,Karim Fizazi,Paul N. Mainwaring,Josep M. Piulats,Siobhan Ng,Joan Carles,Peter F.A. Mulders,Ethan Basch,Eric J. Small,Fred Saad,D. Schrijvers,Hendrik Van Poppel,Som D. Mukherjee,Henrik Suttmann,Winald R. Gerritsen,Thomas W. Flaig,Daniel J. George,Evan Y. Yu,Eleni Efstathiou,Allan J. Pantuck,Eric Winquist,Celestia S. Higano,Mary-Ellen Taplin,Youn C. Park,Thian Kheoh,Thomas W. Griffin,Howard I. Scher,Dana E. Rathkopf +32 more
TL;DR: Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer.
Journal ArticleDOI
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan,Matthew R. Smith,Karim Fizazi,Fred Saad,Peter F.A. Mulders,Cora N. Sternberg,Kurt Miller,Christopher J. Logothetis,Neal D. Shore,Eric J. Small,Joan Carles,Thomas W. Flaig,Mary-Ellen Taplin,Celestia S. Higano,Paul de Souza,Johann S. de Bono,Thomas W. Griffin,Peter De Porre,Margaret K. Yu,Youn C. Park,Jinhui Li,Thian Kheoh,V. Naini,Arturo Molina,Dana E. Rathkopf +24 more
TL;DR: Treatment with abiraterone acetate prolonged overall survival compared with prednisone alone by a margin that was both clinically and statistically significant, and further support the favourable safety profile of abiraton acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.
Journal ArticleDOI
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
Joaquim Bellmunt,Christine Theodore,Tomasz Demkov,Boris Komyakov,Lisa Sengeløv,Gedske Daugaard,Armelle Caty,Joan Carles,Agnieszka Jagiełło-Gruszfeld,Oleg Karyakin,François-Michel Delgado,Patrick Hurteloup,Eric Winquist,N. Morsli,Yacine Salhi,Stéphane Culine,Hans von der Maase +16 more
TL;DR: Overall response rate, disease control, and progression-free survival were all statistically significant favoring VFL + BSC, and therefore, VFL seems to be a reasonable option for TCCU progressing after first-line platinum-based therapy.
Journal ArticleDOI
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
Leticia De Mattos-Arruda,Leticia De Mattos-Arruda,Leticia De Mattos-Arruda,Regina Mayor,Charlotte K.Y. Ng,Britta Weigelt,Francisco Martínez-Ricarte,Francisco Martínez-Ricarte,Davis Y. Torrejon,Mafalda Oliveira,Alexandra Arias,C. Raventós,Jiabin Tang,Elena Guerini-Rocco,Elena Martínez-Sáez,Sergio Lois,Oscar Marín,Xavier de la Cruz,Xavier de la Cruz,Salvatore Piscuoglio,Russel Towers,Ana Vivancos,Vicente Peg,Santiago Ramón y Cajal,Santiago Ramón y Cajal,Joan Carles,Jordi Rodon,Maria Gonzalez-Cao,Josep Tabernero,Josep Tabernero,Enriqueta Felip,Enriqueta Felip,Joan Sahuquillo,Joan Sahuquillo,Michael F. Berger,Javier Cortes,Javier Cortes,Jorge S. Reis-Filho,Joan Seoane,Joan Seoane,Joan Seoane +40 more
TL;DR: It is shown that ctDNA derived from central nervous system tumours is more abundantly present in the cerebrospinal fluid (CSF) than in plasma, allowing the identification of actionable brain tumour somatic mutations and facilitating and complement the diagnosis of leptomeningeal carcinomatosis.